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Abstract 
The VRK1 kinase is a novel Ser-Thr kinase in the human kinome that diverged from the 
casein kinase 1 branch. These kinases phosphorylate transcription factors related to 
stress responses, such as p53. In this report we have studied the phosphorylation of the 
transcription factor c-Jun in its N-terminal region. The VRK1 protein phosphorylates c-
Jun with a Km of 0.4 µM, and is not inhibited by SP600125. VRK1 phosphorylates c-
Jun in Ser63 and Ser73 in vitro, the same residues targeted by the N-terminal kinase of 
c-Jun (JNK). This phosphorylation induces the stabilization and accumulation of the c-
Jun protein. VRK1 phosphorylates the endogenous c-Jun in Ser63. VRK1 activates c-
Jun dependent transcription, which is dependent on phosphorylation of Ser63 and 
Ser73. The c-Jun with Ser63Ala and Ser73Ala substitutions is not transcriptionally 
active when cotransfected with VRK1. VRK1 interacts with c-Jun but not with JNK. 
The cotransfection of VRK1 and JNK has an additive effect on the transcriptional 
activation of c-Jun indicating that they can cooperate when both are at suboptimal dose; 
otherwise maximum effect by one of them prevents the effect of the other. The VRK1-
c-Jun connection represents a component of a new signaling pathway whose upstream 
elements remain to be identified. 
 
INTRODUCTION 
A new family of Ser-Thr kinases has been identified by the homology of their 
catalytic domain to the vaccinia virus B1R kinase (Nezu et al., 1997). Based on the 
latest information from the human kinome (Manning et al., 2002), there are three 
members in this family, known as vaccinia-related kinases (VRK). These proteins have 
a kinase domain with some distant homology to human casein kinase 1 (Lopez-Borges 
& Lazo, 2000; Nichols & Traktman, 2004) from which they diverged early in evolution 
(Manning et al., 2002). However, these three kinases differ significantly in their 
regulatory domains, which are located at the C-terminus in the case of VRK1 and 
VRK2, and at the N-terminus in VRK3. VRK1 is highly express in tumor cells with 
high proliferation rates (Nezu et al., 1997). In developing murine embryos, also VRK1 
and VRK2 are highly express in midgestation, when proliferation of hematopoietic cells 
is extremely high (Vega et al., 2003). Also the substrate characteristics are different 
from those of casein kinase 1 (Lopez-Borges & Lazo, 2000). VRK1 is a nuclear kinase, 
detected in both murine and human cells, that regulates p53 by phosphorylation in 
Thr18 (Barcia et al., 2002; Lopez-Borges & Lazo, 2000). Because of the relation of p53 
to cellular stress responses we decided to determine whether the VRK1 kinase was also 
able to phosphorylate other proteins which are known to be involved in response to 
different types of stress signals. One of these potential candidates is the c-Jun 
transcription factor.  
Many cellular responses to stress are regulated by AP1 binding sites on DNA 
(Eferl & Wagner, 2003). These sites are recognized by transcription complexes form by 
dimers of different protein families. The AP1 transcription complex is formed by a 
protein dimer in which there are many different subunits that can be combined (Dlakic 
et al., 2001; Kerppola & Curran, 1993; van Dam & Castellazzi, 2001). All of them have 
a DNA binding domain and a dimerization domain containing a leucine zipper. These 
proteins belong to any of the families of transcription factors such as JUN, FOS, ATF 
and MAF (musculoaponeurotic fibrosarcoma) (Eferl & Wagner, 2003). The individual 
members of the dimer to form a complex can belong to any of the groups; therefore 
there are a very large number of combinations that might modulate gene expression. 
Their different combinations offer the possibility of fine tuning the control of 
transcription (Shaulian & Karin, 2001; Shaulian & Karin, 2002; van Dam & Castellazzi, 
2001). The  nature of the complex influence the specifity of the recognition sites, thus 
the c-Jun and ATF2 heterodimer recognizes the CRE  sites (cAMP response 
elements)(Hai & Hartman, 2001; Shuman et al., 1997). ATF2 is also phosphorylated by 
VRK1 in novel residues and has an additive effect with JNK (Sevilla et al., 2004). 
These transcription complexes are implicated in the control of cell proliferation, 
differentiation and apoptosis by regulating gene expression (Shaulian & Karin, 2001). 
The c-Jun protein is regulated in response to many types of signals including growth 
factors (Hall et al., 2003), pro-inflammatory cytokines (Dong et al., 2000; Weiss et al., 
2000), oxidative stress (Clerk & Sugden, 1997) and UV irradiation (Adler et al., 1995). 
The c-Jun protein has an amino terminal regulatory domain that is modified by 
phosphorylation, and a carboxy terminal DNA binding domain. The phosphorylation 
implies the binding of the JNK protein to its target c-Jun, and the residues 
phosphorylated are Ser63 and Ser73. The phosphorylated c-Jun protein is then 
transcriptionally active. In the cell phosphorylation of c-Jun occurs as a response to 
many different types of stress signals mediated by a group of serine-threonine kinases, 
the mitogen-activated protein kinases (MAPK) that include ERK, and JNK (Chang & 
Karin, 2001; Davis, 2000; Leppa & Bohmann, 1999). 
 The implication of c-Jun in so many different types of cellular functions in 
response to a very heterogeneous group of signals suggests it is likely that in the cell 
there might be more kinases implicated in regulating its transcriptional activity. 
Therefore we have studied if the recently identified vaccinia-related kinase 1 (VRK1) 
that phosphorylates p53 (Lopez-Borges & Lazo, 2000), another molecule implicated in 
stress responses, could also phosphorylate the c-Jun protein. In this report it is 
demonstrated that VRK1, not only targets c-Jun, but that it can also cooperate with the 
N-terminal Jun kinase.  
 
MATERIAL AND METHODS 
 
Fusion proteins 
The GST-c-Jun (1-223) fusion protein and its double mutant with the Ser63 and73  
 residues substituted by Ala were a gift of M. Karin (San Diego, CA). The GST-VRK1 
fusion protein has been previously described (Lopez-Borges & Lazo, 2000). 
 
Plasmids 
The human VRK1 protein was expressed from constructs pCDNA-VRK1-Myc or 
pCMV-HA-hVRK1, and pCMV-HA-hVRK1 (K179E) that have the coding VRK1 
sequence tagged with the Myc or HA epitopes. The exogenous kinase was pHA-JNK 
from S. Gutkind (NIH, Bethesda, MD). Plasmid pCMV-HA-c-Jun was from D. 
Bohmann (EMBL, Heidelberg, Germany). For reporter assays of luciferase activity the 
following plasmids from M. Karin (University of California, San Diego) were used, the 
5 x GAL4-Luc (reporter), and GAL4-c-Jun (pSG424 Gal4-c-Jun, residues 1-257) and 
GAL4-c-Jun S63/73A (pSG424 Gal-4 c-Jun S63/73A, residues 1-257) expression 
vectors encode fusion proteins containing the GAL4 DNA-binding domain and the c-
Jun activation domain in wild type and mutant forms (not phosphorylatable by mutation 
of both serines 63 and 73 to alanine). As internal control in transcription assays we used 
the pRL-tk plasmid from Promega (Madison, WI).  
 
Kinase activity assay. 
Kinase activity was determined by assaying protein phosphorylation in a mixture 
containing 20 mM Tris-HCl, pH7.5, 5 mM MgCl2, 0.5 mM dithiothreitol, 150 mM KCl 
and 5 µM (5 µCi) [γ-32P]-ATP, 5 µg of GST-VRK1 protein and 10 µg of another 
protein as substrate when indicated. The reaction was routinely performed for 30 
minutes at 30ºC (Barcia et al., 2002; Lopez-Borges & Lazo, 2000). The specific 
inhibitor for JNK, SP600125 was from Sigma. For the kinetic analysis the reaction 
conditions were similar with the exception that the amount of GST-c-Jun varied as 
indicated in the corresponding experiment. Always the reaction was performed in the 
linear response range of incorporation of radioactivity. Quantitation was performed by 
two different techniques, direct quantitation in a BioRad personal phosphorimager or by 
exposure to X-ray film in the linear response range and quantitation of the bands by 
densitometry. With both methods the same results were obtained, where the Vmax was 
always determined in arbitrary units as pixels per surface area unit. 
 
Acid hydrolysis and phosphoaminoacid analysis. 
An in vitro kinase assay was performed with GST-VRK1 and the GST-c-Jun or GST c-
Jun S63/73A as substrates. The phosphorylated proteins were fractionated by an SDS-
polyacrylamide electrophoresis and transferred to an Immobilon-P filter (Millipore, 
Bedford, MA) and the radioactive bands corresponding to GST-c-Jun and GST c-Jun 
S63/73A were excised and the protein eluted. The eluted protein was hydrolyzed with 
200 µl of 6N HCl at 110ºC for two hours. The sample was freeze-dried and resuspended 
in a mixture containing 2 µl of a stock solution at 1mg/ml of P-Ser, P-Thr and P-Tyr as 
reference markers, 1 µl of 1% bromophenol blue and 2 µl of formic acid/acetic 
acid/water (1:3.1:35) mix at pH1.9. The mixture was applied to a cellulose 
chromatoplaque (Merck, Darmstadt, Germany) and subject to flat bed electrophoresis in 
a Multiphor II system (Amersham Biosciences, Little Chalfont, UK) at 1.5 kV for 90 
min. After air drying, the radioactivity on the chromatoplaque was analyzed with a FX 
Personal Imager (BioRad, San Diego, CA) or exposed to X-ray film. The 
phosphoaminoacid markers were detected by staining with a 0.25 % ninhydrin solution 
in acetone. 
 
Tryptic phosphopeptide map analysis. 
GST-c-Jun and GST c-Jun S63/73A phosphorylated proteins were isolated from 
an Immobilon-P membrane (Millipore). The band with the phosphorylated protein was 
excised, incubated with 0.5 % polyvinyl-pyrrolidone in 100 mM acetic acid for 30 
minutes at 37 ºC, followed by extensive washes with water and fresh 50 mM NH4HCO3. 
The membrane was incubated twice, with 10 µg of trypsin (Roche Diagnostics, 
Mannheim, Germany) in 50 mM NH4HCO3, pH 8.0 for 2 hours at 37ºC, and a third time 
for 18 hours. The membrane was extensively washed with sterile distilled water. The 
washes were freeze-dried, and oxidized with 9:1 performic acid/hydrogen peroxide for 1 
hour at room temperature, followed by freeze-drying. The sample was resuspended in 5 
µl of formic acid: acetic acid: water (1:3.12:35.88) pH1.9 and applied to a 
chromatoplaque (Merck, Darmstadt, Germany). The first dimension was an 
electrophoresis at 1.5 kV for 90 min in a Multiphor system (Pharmacia, Uppsala, 
Sweden). The chromatoplaque was left to air dry, and turned 90 degrees for the second 
dimension. The second dimension was a chromatography performed in acetic acid: 
pyridine: n-butanol: water (1:3.33:5:4) for 13 hours. The plaque was left to air dry and 
radioactivity was detected using an X-ray film or by a phosphorimager system (BioRad, 
San Diego, USA). 
 
Cell lines and Transfections 
NIH 3T3 and 293T human embryo kidney cells were grown in Dulbecco´s modified 
Eagle´s medium (DMEN) supplemented with 10% fetal bovine serum (FBS), 1% L- 
glutamine and 1% penicillin-streptomycin at 37ºC in a humidified atmosphere of 5% 
CO2. Transfections were performed by the calcium phosphate method or with JetPEI 
reagent (Polytransfection, Illkirch, France) according to manufacturer 
recommendations. The total amount of DNA within the experiments was kept constant 
by adding the respective empty vector plasmid DNA to the transfection mixtures. In 
experiments using 293T cells, usually 1.5 x 106  cells were plated in a P100 dish, or 5 x 
105 in a P60 dish 16 hours prior to transfection. For NIH 3T3 cells, 3 x 105 cells were 
seeded in a P60 dish. 
 
Immunoblots 
Whole cell extracts were collected 48 hours postransfection. The cell monolayer was 
washed twice in PBS and the cells lysed by incubation in RIPA buffer (150 mM NaCl, 
1,5 mM MgCl2, 10 mM NaF, 10% glycerol, 4 mM EDTA, 1% Triton X-100, 0.1% 
SDS, 1% Deoxycholate, 50 mM Hepes, pH 7.4), plus 1 mM Na3VO4, 10 µg/ml 
leupeptin, 10 µg/ml aprotinin and 1mM PMSF for 30 min on ice and precleared by 
centrifugation at 13,000 rpm for 20 min at 4ºC. The extracts were analyzed by SDS-
PAGE under denaturing conditions and transferred to Immobilon-P membranes 
(Millipore, Bedford, MA). The membranes were blocked with 5% skimmed milk in 
TBS-T, and then incubated with the specific antibody, anti-HA at 1:1000 dilution 
(Covance, Berkeley, CA) or a rabbit anti-VRK1 polyclonal antibody at 1:500 dilution. 
The c-Jun phosphorylated in Ser63 was detected with a specific antibody from Cell 
Signaling at a 1:1000 dilution (Beverly, MA) after blocking the membrane with 1% 
BSA. As secondary antibody a rabbit anti-mouse IgG or a goat anti-rabbit IgG with 
peroxidase were used at a dilution of 1:10.000 and the blot was developed with an ECL 
chemiluminescence kit from Amersham Bioscience.   
 
Immunofluorescence and confocal microscopy.   
HeLa cells were grown on uncoated glass coverslips introduced into 100-mm plates 
(150,000 cells/plate).  30 hours post-transfection using JetPEI, (Polytransfection, 
France) cells were rinsed twice in PBS, fixed with 3.7% paraformaldehyde in PBS for 
15 min at room temperature, permeabilized by incubation with PBS containing 0.5% 
Triton X-100 for 15 min, and were then treated with 0.1M glycine in PBS for 15 min. 
Non specific sites were blocked by incubation with PBS containing 1% BSA for 30 min 
at room temperature. Cells were then washed in PBS containing 0.05% Tween-20 for 5 
min and incubated with the primary antibodies diluted in PBS for 1 hour at room 
temperature. After that, cells were incubated with one of the following secondary 
antibodies:  anti mouse secondary antibody coupled to Cy2 (Sigma) (1:200 dilution), 
anti- rabbit secondary antibody coupled to Cy3 (Sigma) (1:200 dilution). Fluorescence 
images were captured with a Zeiss LSM 510 confocal microscope. Fluorochromes were 
excited using an 18Argon laser (488 nm excitation–wavelength) for Cy2 and a  2He/10Ne 
laser ( 543 nm excitation –wavelength ) for Cy3. 
 
Transcriptional assays.  
Reporter gene assays were performed with the Dual-Luciferase reporter assay system 
(Promega) in cell extracts prepared at 36-48 hours after transfection. The assay is based 
on the use of p SG-424-c-Jun or pSG-424-c-Jun S63/73A constructs with a GAL4DNA 
binding domain and a p5xGAL4-Luc reporter that were cotransfected in each sample in 
combination with pRL-tk Renilla luciferase as an internal control for transfection 
efficiency. The total amount of DNA within the experiments was kept constant  by 
adding the respective empty vector plasmid DNA to the transfection mixtures. 
Luciferase activity was determined with 20 µl of total cell extract using the Dual 
Luciferase reporter assay kit from Promega (Madison, WI). The generated light was 
detected with an OPTOCOM-1 luminometer (MGM Instruments, Inc., Hamden, CT) as 
previously described (Hernandez-Torres et al., 2001; Yunta et al., 2002)]. The activity 
of the reporter luciferase was expressed relative to the activity in control vector 
transfected cells. Transcription reporter experiments were performed in triplicate. All 
results were analyzed  by comparing with the control (unpaired Student´s test) and in 
the figures are shown the mean ± SD of  independent triplicate cultures as well as the P-
value. 
 
 
RESULTS 
 
VRK1 and c-Jun co-localize in the nucleus 
 For a protein to be an immediate target of another means that both have to be 
located in the same subcellular compartment. Therefore the subcellular location of both 
VRK1 and c-Jun was determined in HeLa cells. For these experiments the cells were 
transfected with tagged proteins and expressed from expression vectors. VRK1-myc and 
HA-c-Jun were transfected and their location was determined by immunofluorescence 
and confocal microscopy. As shown in Fig.1, both VRK1 and c-Jun are located in the 
nuclei, but outside the nucleolus. This data indicates that when there are high levels of 
both proteins they are found in the same nuclear compartment.  
 
VRK1 phosphorylates c-Jun in vitro and is insensitive to SP600125 
The c-Jun transcription factor is regulated by reversible phosphorylation that is carried 
out by different kinases depending on the type of signal. The c-Jun protein is a potential 
target for the nuclear VRK1 activity. Therefore, to determine if c-Jun could be 
phosphorylated in vitro, a kinase assay with the GST-VRK1 (full length) protein was 
carried out to detect the phosphorylation of the N- terminal domain of c-Jun, as a GST-
c-Jun (1-223) fusion protein. As shown in Fig.2 A, VRK1 phosphorylates c-Jun but not 
the GST protein moiety. If the GST-VRK1 fusion protein contained a shorter segment 
of c-Jun (residues 1-79), phosphorylation was lost probably because the target residues 
are very proximal to the C-terminus of the molecule and do not fold properly (Lopez-
Borges & Lazo, 2000). Next we performed a kinase analysis where the c-Jun 
concentration was variable in order to determine the affinity of VRK1 for c-Jun. VRK1 
has an affinity for c-Jun, with a Km of 0.4 µM (Fig.2B), which is well suited for the 
intracellular concentrations of the c-Jun protein. The strong signal of the GST-VRK1 
protein is due to the high autophosphorylation activity of this kinase (Barcia et al., 
2002; Lopez-Borges & Lazo, 2000). 
 Next it was determined if SP600125, a very potent inhibitor of JNK kinase 
activity  (Bennett et al., 2001; Han et al., 2001) could affect VRK1 kinase activity. In an 
in vitro kinase assay, a wide range of SP600125 concentrations were used (Fig. 2C). 
VRK1 was not affected even by concentrations that were up to two orders of magnitude 
higher than the one, IC50 = 0.09 µM, required for JNK inhibition (Bennett et al., 2001; 
Han et al., 2001). Therefore, we can conclude that the activity of VRK1 is not sensitive 
to the SP600125 inhibitor (Fig. 2C), since it does not inhibit the autophosphorylation or 
the phosphorylation of c-Jun. VRK1 protein with the K179E substitution in the active 
site has no kinase activity on itself nor on c-Jun (Fig. 2C). 
 
c-Jun is phosphorylated in Ser63 and Ser73 by VRK1 
 To identify the residues phosphorylated by VRK1 in the c-Jun molecule we 
performed a phosphoaminoacid analysis using as substrate the GST-c-Jun fusion protein 
and its mutant form where Ser63 and Ser73 have been replaced by alanine. Both Ser and 
Thr residues are phosphorylated (Fig.3A). The incorporation of radioactivity in the 
phospho-Ser position falls by more than 80 percent when the Jun Ser 63,73 Ala mutant 
was used, suggesting that these residues are likely to be the main targets for VRK1 
phosphorylation. In addition there is a strong phosphorylation of Thr residues in the c-
Jun molecule as shown by the spot corresponding to phospho-Thr (Fig.3A). In order to 
identify the phosphorylated residues we also performed a phosphopeptide map of the 
phosphorylated GST-c-Jun and of its double mutant containing the S63A and S73A 
substitutions, which are the residues targeted by JNK. The phosphopeptide of the c-Jun 
double mutant, S63A and S73A, resulted in the loss of a peptide (Fig. 3B); however 
there were still several other phosphorylated peptides, which accounted for the lack of 
total loss of signal in the phosphoaminoacid analysis. These additional peptides are 
likely to result from the phosphorylation in Thr residues, although some additional 
phosphorylation in other Ser residues can not be excluded. 
 
 
 
VRK1 stabilizes c-Jun 
 The phosphorylation of c-Jun by other kinases, such as JNK, resulted in an 
increase in its stability and consequently in an increase in the intracellular levels of the 
c-Jun protein, because the phosphorylated molecules can dimerize, preventing their 
binding to ubiquitin ligase (Fuchs et al., 2000). Therefore, we performed an experiment 
to test if VRK1 could also induce a c-Jun accumulation as result of its phosphorylation. 
For this aim 293T cells were transfected with pHA-VRK1 and a fixed amount of pHA-
c-Jun. The levels c-Jun and VRK1 were determined by immunoblots with an anti-HA 
antibody (Fig.4A). EGFP protein under the promoter of CMV was also transfected and 
the levels of EGFP determined by western blot. The levels of EGFP were not affected 
by increasing the amount of transfected VRK1, ruling out and effect on the CMV 
plasmid promoter (Fig. 4A). 
 To further demonstrate the specificity of this accumulation, similar experiments 
were performed using an inactive kinase by introducing a specific substitution in the 
catalytic site, the VRK1 (K179E) mutant. When this inactive kinase was used there was 
a loss of the c-Jun accumulation (Fig. 4B), suggesting that it was a consequence of the 
phosphorylation by this kinase. 
 To confirm that the VRK1 effect is associated with c-Jun phosphorylation, the 
phosphorylation of the endogenous c-Jun protein in residue Ser63 was determined, with 
a specific anti phospho-specific antibody, in 293T cell transfected with increasing 
amounts of VRK1. As the amount of VRK1 was increased so did the phosphorylation of 
the endogenous c-Jun in Ser63 (Fig. 4C). 
  
VRK1 stimulates c-Jun dependent transcription 
 Because of the phosphorylation of residues Ser63 and Ser73 in the c-Jun molecule, 
which are identical to those phosphorylated by the c-Jun N2-terminal kinase (JNK), it is 
very likely that the VRK1 activity will also modulate c-Jun dependent transcription. To 
study the possible effect of VRK1 on the transcriptional activity of c-Jun, we tested the 
effect by transient transfection in NIH3T3 cells with different combinations of kinases 
and c-Jun substrates (wt or mutant), in a reporter system consisting in the fusion of the 
N-terminus of c-Jun with a GAL4 DNA binding domain (c-Jun-GAL), and a luciferase 
reporter vector 5xGAL4-luciferase. The reporter construct was activated when 
recognized by dimers of the DNA binding domain, which only occurs when the c-Jun 
moiety of the fusion protein was phosphorylated. First a dose-response analysis was 
performed in 293T cells using different amounts of pHA-VRK1 plasmid. As the VRK1 
protein kinase was increased, so was the activation of transcription (Fig. 5A). Next the 
effect was also studied in NIH 3T3 fibroblasts, and the VRK1 effect on transcription 
was compared with that of JNK. In cells transfected with HA-JNK as positive control, 
there was a very important increase in transcriptional activity. The transfection with the 
HA-VRK1 kinase also induced an activation of transcription which was similar to that 
induced by JNK (Fig. 5B). The transcriptional activation of c-Jun by either HA-JNK or 
the HA-VRK1 was completely blocked when the cells were transfected with the mutant 
form of c-Jun containing the double substitution of Ser63 and Ser73 for Ala, as shown 
in Fig.5B. Therefore we can conclude that VRK1 acts as a potent activator of c-Jun 
transcriptional activity by phosphorylation of the same residues as those phosphorylated 
by JNK.  
 
VRK1 interacts with c-Jun but not JNK  
It is possible that the effect of VRK1 might be mediated directly by the interaction of 
VRK1 with c-Jun or indirectly via JNK. To test this possibility 293T cells were 
transfected with a expression plasmids pHA-c-Jun or pHA-JNK in combination with a 
construct expressing pCDNA-VRK1-myc. The transfected cells express very well all 
the constructs, as shown by western blots of the corresponding transfected cells (Fig. 
6A). These extract were used for reciprocal immunoprecipitation and immunoblots (Fig. 
6B). In cells transfected with HA-c-Jun and VRK1-myc, the immunoprecipitation with 
anti-HA brings down VRK1 as detected in the immunoblot. The inverse situation, in the 
immunoprecipitate of VRK1, c-Jun is also detected with the anti-HA antibody (Fig. 6B, 
left). However when the VRK1 and JNK combination was used immunoprecipitation 
with each of them did not bring down the other as shown in the immunoblots (Fig.6B, 
right). These data suggest that VRK1 can interact with c-Jun, but not JNK. However the 
complex is likely to be a minor fraction of the total protein expressed in the cells, since 
only the c-Jun fraction located in the nucleus can interact with VRK1. 
 
VRK1 cooperates with JNK activation of c-Jun 
The utilization by VRK1 and JNK of the same residues as targets in the c-Jun molecule 
suggested that perhaps both kinases could cooperate in c-Jun regulation. To test if the 
activities of JNK and VRK1 have an additive effect, suboptimal concentrations of JNK1 
and VRK1 were selected, such as 0.4 µg or 0.8 µg of each kinase expression plasmid, 
and used for transfection of 293T cells. As shown in Fig. 7, the suboptimal 
concentration of each kinase by itself induces a moderate increase in c-Jun dependent 
transcription. However, the mixture of the two kinases induced an additive effect, which 
is dependent on the amount of kinase transfected. Therefore we concluded that both 
kinases can activate c-Jun in a situation where there is no maximal activation of the 
transcriptional activity of c-Jun. 
 
DISCUSSION 
The phosphorylation of the c-Jun transcription factor by the nuclear VRK1 
protein may represent a novel pathway of c-Jun regulation. The VRK1 kinase is not 
integrated in any known pathway and is not included in the MAPK kinase signaling 
complexes with the JIP-1 proteins. These complexes are formed in the cytoplasm, while 
VRK1 is located in the nucleus. This suggests that while the MAPK kinase complexes 
are implicated mainly in response to extracellular signals, the pathway mediated by 
VRK1 might be a response mechanism to events occurring within the nuclei, which 
may include for example sensor mechanisms of DNA damage. However, the upstream 
regulatory elements of VRK1 are not yet known. In this context, it is interesting to note 
that two of the proteins phosphorylated by VRK1, p53 and c-Jun, are components of the 
cellular mechanisms implicated in the response to different types of stress (Fig. 8). 
The affinity of VRK1 for the c-Jun protein is well suited to respond to 
fluctuations in its intracellular concentration. Thus, if by any stimuli the level of c-Jun 
protein increases in the nuclei; it will be phosphorylated and thus become 
transcriptionally active. The phosphorylation of c-Jun in Ser63 and Ser73 suggest that 
these residues can be phosphorylated independently of the c-Jun activation by JNK, as 
shown by the additive effect on c-Jun transcriptional activation by JNK and VRK1. 
Furthermore both kinases can reach a similar level of maximal activation of c-Jun 
transcriptional activity indicating that the VRK1 pathway is likely to be independent of 
JNK, but at least part of its transcriptional effects might be the same. There is an 
important functional difference between JNK and VRK1. JNK is activated in the 
cytosol and forms a stable complex with c-Jun that is translocated to the nuclei. On the 
other hand VRK1 is already in the nuclei and its substrate is only the fraction of  c-Jun 
molecules located within the nuclei. This fact can explain that the amount of c-Jun 
forming a stable complex is small in the VRK1 immunoprecipitate, since it represents a 
subpopulation of c-Jun molecules within the nucleus. Therefore, there is a 
compartmentalization regarding the interaction between the kinase and its substrate. In 
those situations where the JNK-c-Jun complex is already formed in the cytosol and 
translocated to the nucleus, it is unlikely that there could be an additional effect of 
VRK1 since JNK would physically prevent the interaction of VRK1 with c-Jun, or the 
c-Jun is already phosphorylated. The additive effect of c-Jun phosphorylation by VRK1 
and JNK suggests two potential consequences of phosphorylation. One is that the two 
pathways can activate c-Jun in an additive manner if the activation occurs at suboptimal 
doses. The alternative would be that maximal activation by one pathway will prevent 
activation by the second pathway. In this latter case the biological differences will be 
determined by the different substrate specificity of the kinases involved. 
Most studies on c-Jun regulation have been performed under catastrophic or 
massive stress conditions that are unlikely to represent its the biological selection during 
evolution, since they are stress of a type or magnitude never detected by normal cells 
such as irradiation at very high doses or chemotherapeutic drugs. The magnitude of 
normal damage is much lower and suboptimal, and that is the one that participated 
during evolution, therefore c-Jun must have a much more subtle regulation, and VRK1 
might be one of these regulatory elements. c-Jun is required for normal cell proliferation 
and under severe stress conditions an apoptotic reaction is often started (Dunn et al., 
2002). In the absence of stress stimulation, perhaps the role played by VRK1 is that of 
maintaining a basal activity of AP1 dependent transcription that requires c-Jun as part of 
the transcription factor dimer. However, the fine tuning of these mechanism and their 
implication in oncogenesis are far from being well characterized, suggesting c-Jun 
regulation is more complex than originally realized (Kennedy & Davis, 2003). 
Alteration in c-Jun levels have been detected in several tumor types, changes that might 
modify the expression of other genes and be oncogenic (Antonyak et al., 2002; Aoyagi 
et al., 1998; Meggiato et al., 2003; Neyns et al., 1996; Szabo et al., 1996; Tiniakos et al., 
1994; Volm et al., 2002; Wodrich & Volm, 1993). 
In this report we have demonstrated that VRK1 can regulate c-Jun dependent 
transcriptional activity, which can cooperate with other kinases, such as JNK. These 
results are a contribution to the elucidation of the potential roles of the VRK1 protein in 
cell biology, representing an additional step in the characterization of a new signaling 
pathway. 
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Figure Legends 
 
Figure 1. Nuclear colocalization of human VRK1 and c-Jun in HeLa cells. HeLa cells 
were transfected with VRK1 tagged with a myc epitope and c-Jun tagged with an HA 
epitope. Each specific epitope was detected with a primary antibody for tag followed by 
a different secondary antibody labeled with Cy2 and Cy3 respectively. Interphase nuclei 
were identified by DAPI staining. 
 
Figure 2. A. Phosphorylation of the N-terminus of c-Jun by the human VRK1 protein. 
Both proteins were used as GST-fusion proteins in an in vitro kinase assay. At the 
completion of the reaction the samples were loaded in an SDS- polyacrylamide gel. In 
the left panel is the Coomassie blue staining and in the right panel is shown the 
incorporation of radioactivity. B. Kinetics of VRK1 phosphorylation of the c-Jun 
protein. As substrate a GST-c-Jun fusion protein was used in the assay and its 
concentration was changed as indicated, the quantification was performed in the linear 
response range of all parameters. C. Effect of different concentrations of SP600125 on 
the autophosphorylation activity of VRK1 (left panel) or lack of effect of 25 µM 
SP600125 on the phosphorylation of GST-c-Jun (right panel). Also is included an assay 
with the inactive mutant VRK1 (K179E) to show its lack of activity (right panel). Both 
incorporation of radioactivity and the amount of protein in the gel (Coomassie) are 
shown. 
 
Figure 3. A. Phosphoaminoacid analysis of the wild type GST-c-Jun and mutant GST-
c-Jun (Ser 63,73 Ala). The intensities of the spots were quantified in a phosphorimager 
system. The arrow indicates the loss of  serine phosphorylation in the c-Jun double 
mutant. B. Phosphopeptide analysis of GST-c-Jun and mutant GST-c-Jun (Ser 63, 73 
Ala), first dimension is a high voltage electrophoresis and the second dimension is a 
thin layer chromatography. The arrow indicates the spot that disappears in the double c-
Jun mutant. 
 
Figure 4. A. Accumulation of c-Jun by increasing the amount of transfected HA-VRK1 
(pCMV-HA-hVRK1) in 293T cells; the control protein GFP expressed under the same 
promoter is not affected by increasing concentrations of the kinase. 293T cells (1.5 x 
106) were transfected with 1 µg of HA-c-Jun and increasing amounts of the HA-VRK1 
kinase (pCMV-HA-hVRK1). The amount of DNA in the transfection was kept constant 
by the addition of empty expression vector.  B. The inactive kinase VRK1 (K179E) 
does not induce the accumulation of c-Jun. At the bottom is shown the quantification 
and relative effect of the kinase, wild-type or inactive mutant (K179E), on the 
accumulation of c-Jun. Quantification was performed in the linear response range of all 
signals. β-actin was used as a gel load control. C. The phosphorylation of the 
endogenous c-Jun in Ser63 increases with increasing amounts of transfected VRK1 
((pCMV-HA-hVRK1). Phosphorylation of c-Jun phosphorylated in Ser63 was detected 
with an antibody specific for this phosphorylation from Cell Signaling. The control are 
cells transfected with empty vector.  
 
Figure 5. A. Dose response analysis of transcription activation by VRK1 using a 
dimerization dependent-assay in transfected 293T cells (5 x 105 cells per plate). 
B.VRK1 phosphorylation induces the transcriptional activity of c-Jun. NIH3T3 
fibroblast were transfected with the control plasmid or with either 3 µg of HA-JNK 
(pHA-JNK) or 3 µg of HA-VRK1 (pCMV-HA-hVRK1). In the reporter system the 
following plasmids were used as indicated, 1 µg of 5 x GAL4-Luc (reporter), and 1 µg 
of GAL4-c-Jun (1-257) or 1 µg of GAL4-c-Jun (1-257, S63/73A) expression vectors 
encoding for fusion proteins containing the GAL4 DNA-binding domain and the c-Jun 
activation domain (residues 1-257) in wild type and mutant forms (not phosphorylatable 
by substitutions of serine 63 and 73 by alanine). For normalization of the transfection 
efficiency 0.5 µg of the plasmid pRL-tk, Renilla luciferase reporter, was included in the 
transfection. The total amount of DNA in the transfection was kept constant at 5.5 µg by 
the addition of empty vector. Three independent experiments were performed. 
 
Figure 6. Interaction of VRK1 with c-Jun (A) or JNK (B). At the top is shown the 
immunoblot of whole cell extracts of cells (1.5 x 106 cells/dish) transfected with either 
the combination of 4 µg of VRK1 (pCDNA-hVRK1-Myc) and 4 µg of pHA-c-Jun (A 
top) or 4 µg of  VRK1 (pCDNA-hVRK1-Myc) and 4 µg of  HA-JNK (pHA-JNK) (B 
top). The transfected proteins were detected by immunoblot with a commercial antibody 
against the specific tag (HA epitope) or a polyclonal antibody specific for VRK1 (top 
panels).  These extract were used for the reciprocal immunoprecipitation followed by 
immunoblot (WB) of cells transfected with VRK1 (pCDNA-hVRK1-Myc) and pHA-c-
Jun in part A of the figure, in both immunoprecipitates the other protein is detected (A, 
bottom). The reciprocal immunoprecipitation followed by immunoblot from cells 
transfected with VRK1 (pCDNA-hVRK1-Myc) and pHA-JNK (B, bottom) was also 
performed. In these immunoprecipitates is not detected by western blot the second 
protein, suggesting VRK1 and JNK do not interact. Immunoprecipitations were 
performed with commercial antibodies specific for the HA or Myc epitopes, and the 
western blots were performed with either a commercial antibody for the HA epitope or a 
polyclonal antibody specific for the VRK1 protein. 
 
Figure 7. Cooperation between JNK and VRK1 in c-Jun activation. 293T cells were 
transfected with different amounts of HA-JNK (pHA-JNK ) or HA-VRK1 (pCMV-HA-
hVRK1) by themselves or in combination using as reporter system 5 x GAL4-Luc (1 
µg),  GAL4-c-Jun (1 µg) and 0.5 µg of the plasmid pRL-tk. Activation of c-Jun by 
either transfected HA-JNK or HA-VRK1; and additive effect of suboptimal 
concentrations of HA-JNK (pHA-JNK) and HA-VRK1 (pCMV-HA-hVRK1) on the 
transcriptional activity of c-Jun. Mean with SD from three independent experiments are 
shown. ** P < 0.01. 
 
Figure 8. Diagram illustrating signaling pathways and the targets of VRK1 and signals 
converging on c-Jun. VRK1 forms a complex with non-phosphorylated c-Jun in the 
nucleus and therefore represent a subpopulation of the total c-Jun protein in the cell. 
JNK binds to c-jun in the cytosol and the complex is translocated to the nucleus where 
they dissociate, but this c-Jun that has been phosphorylated by JNK can not be a target 
for VRK1. 
 
 
 
 
 








